Targeted therapies for genetically-defined leukaemias were a major theme amongst the top abstracts at the 63rd ASH Annual Meeting and Exposition. Professor Hartmut Döhner presented results from the AGILE study which found ivosidenib and azacitidine significantly improved outcomes compared to azacitidine and placebo in patients with newly diagnosed AML and an isocitrate dehydrogenase 1 (IDH1) ...
Hard to treat AML with genetic risk responds to targeted therapy with ivosidenib
By Mardi Chapman
10 Jan 2022